Product Details
Ajovy
Fremanezumab225 mg/1.5 mL (150 mg/mL)
Solution for Subcutaneous Injection
Single-Dose 1.5-mL Pre-Filled Autoinjector (Preservative-Free)
DIN/PIN/NPN
02509474
Manufacturer
Teva Canada Innovation.
Formulary Listing Date
2023-04-28
Unit Price
560.9800
Amount MOH Pays
560.9800
Coverage Status
Exceptional Access Program Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
N02CD03
Interchangeable Products
NOLU Clinical Criteria
NOEAP Criteria
Therapeutic Class | Reimbursement Criteria |
---|---|
Migraine Drugs | Fremanezumab
Initiation Criteria: For the prophylaxis of headaches in adults meeting the following criteria:
1Inadequate response is defined as no therapeutic or unsatisfactory effect (less than 30% reduction in frequency of headache days) to an adequate dose and duration of 2 oral prophylactic medications2 where both medications must be of different types/classes. Contraindication or intolerable side effects necessitating discontinuation will be considered for 1 of the 2 drugs only. 2Oral prophylactic therapy types/classes to be considered include:
Initial requests should contain the following information:
Dosing: As per product monograph Duration of Approval: 6 months Renewal criteria: Objective evidence demonstrating that the patient has achieved or maintained an adequate treatment response, defined as:
Renewal requests should contain the following information:
Dosing: As per product monograph |